Plexxikon Inc.

Gilead Sciences, Inc.

Nurix Therapeutics, Inc.

Opna Bio Sa

Opna Immuno-oncology Sa

John Buell

Wayne Spevak

Jiazhong Zhang

Phuongly Pham

Guoxian Wu

Songyuan Shi

Ying Zhang

Jack Lin

Zuojun Guo

Prabha N Ibrahim

Jeffrey Yung Wu

Aaron Edward Albers

Hannah Powers

Katrina Chan

Chao Zhang

Jack Walleshauser

Jeffrey Wu

Aaron Albers

Hunter Paul Shunatona

Cuong Q Ly

Mark Vander Wal

Scott A Mitchell

Frederick Cohen

Marika Nespi

Todd Ewing

Hiroaki Inagaki

Elizabeth A Burton

Galen Paul Shearn-Nance

Ken Dong

Lan Wang

Garson Tsang

Yongil Jin

Ryan Pemberton

Mark Edward Zak

Compounds and methods for CD73 modulation and indications therefor

The present disclosure provides bifunctional compounds as HPK1 degraders via ubiquitin proteasome pathway, and method for treating diseases modulated by HPK1.

Bifunctional degraders of hematopoietic progenitor kinase and therapeutic uses thereof

The present disclosure provides bifunctional compounds as HPK1 degraders via ubiquitin proteosome pathway, and method for treating diseases modulated by HPK1.

Compounds and methods for EP300 or CBP modulation and indications therefor

Disclosed are compounds of Formula (I) and (Ia): 

Compounds and methods for IDO and TDO modulation, and indications therefor

Compounds and methods for CDK8 modulation and indications therefor

Heterocyclic compounds of formula (I), methods for their preparation, pharmaceutical compositions containing such a compound and their therapeutic uses.

Heterocyclic compounds and uses thereof

Disclosed are compounds of Formula I(a): 

Compounds active on c-kit protein kinases or mutant c-kit protein kinases having any mutations are described, as well as methods of making and using such compounds to treat diseases and conditions associated with aberrant activity of the c-kit protein kinases and mutant c-kit protein kinases.

Compounds and methods for kinase modulation, and indications therefor

Disclosed are compounds of Formula I(b): or a pharmaceutically acceptable salt, a solvate, a tautomer, an isomer or a deuterated analog thereof, wherein Ring A, Ring HD, J, each T, R, R, R, each R, and m are as described in any of the embodiments described in this disclosure; compositions thereof; and uses thereof.

Compounds of Formula I: or a pharmaceutically acceptable salt, a solvate, a tautomer, an isomer or a deuterated analog thereof, wherein R, R, Q, Q, and Q, are described in this disclosure, compositions thereof, and methods and uses thereof.

Compounds active on c-kit protein kinases or mutant c-kit protein kinases having any mutations are described, wherein the compounds are of Formula (I): Methods of making and using such compounds to treat diseases and conditions associated with aberrant activity of the c-kit protein kinases and/or mutant c-kit protein kinases are also described.

Growing community of inventors

San Francisco, CA, United States of America

John Buell